Based on KEYNOTE-158 Trial, Patients Receiving KEYTRUDA Demonstrated an Objective Response Rate of 46% Approval Marks Fourth Gynecologic Cancer Indication for KEYTRUDA KENILWORTH, N.J.– Merck (NYSE: MRK), known as MSD… Read More
CPE News – Qu Biologics Inc. has announced the closing of a US $12 million equity financing. Qu Biologics did not disclose the names of the investors. The company has… Read More
Vancouver, BC – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces that its Chief Financial… Read More
NanoVation Therapeutics™ (NTx) is pleased to announce the expansion of its global gene therapy builder with the launch of its first GENErator™, NanoVationTx™ UK. The operations of NTx UK will… Read More
The Canadian Society for Immunology (CSI) has awarded Dr. Brad Nelson, distinguished scientist and co-director of BC Cancer’s Immunotherapy Program, with the prestigious 2022 Hardy Cinader Award. This award is… Read More
